Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
EMPLICITI vs SYLVANT
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Elotuzumab is a humanized monoclonal antibody that targets the SLAMF7 (signaling lymphocytic activation molecule F7) receptor expressed on myeloma cells and natural killer (NK) cells. It enhances NK cell-mediated antibody-dependent cellular cytotoxicity (ADCC) via direct activation of NK cells through SLAMF7 and CD16 engagement, and also directly activates NK cells to induce killing of myeloma cells.
Siltuximab is a chimeric monoclonal antibody that binds to human interleukin-6 (IL-6) and prevents its binding to the IL-6 receptor, thereby inhibiting IL-6-mediated signaling and the downstream inflammatory cascade.
FDA-approved: In combination with lenalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received one to three prior therapies,FDA-approved: In combination with pomalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor
Treatment of multicentric Castleman disease (MCD) in patients who are human immunodeficiency virus (HIV) negative and human herpesvirus-8 (HHV-8) negative.,Off-label: Treatment of cytokine release syndrome, Castleman disease in HIV-positive or HHV-8-positive patients, and other IL-6-driven conditions.
10 mg/kg IV weekly for first 8 weeks, then every 2 weeks thereafter; administer with lenalidomide and dexamethasone.
11 mg/kg intravenously every 3 weeks, administered over 1 hour.
Terminal elimination half-life is approximately 26-29 days. This long half-life supports biweekly IV dosing after initial weekly schedule.
Terminal half-life ~21 days (range 14–28 days) at steady state; supports every-3-week dosing.
Elotuzumab is a monoclonal antibody; metabolism involves catabolism via proteolytic degradation into small peptides and amino acids. No specific CYP450 enzyme involvement.
Siltuximab is a monoclonal antibody; its metabolism is not typical. It is degraded into small peptides and amino acids via catabolic pathways, similar to endogenous immunoglobulins. No specific metabolic enzymes are involved.
Empliciti (elotuzumab) is a monoclonal antibody; elimination occurs via intracellular catabolism, yielding amino acids. Renal excretion of intact drug is negligible (<1%). Biliary/fecal excretion is minimal; no specific data on percentage.
Renal (minimal as intact Ig G), primarily catabolized to amino acids; no significant biliary/fecal elimination.
Elotuzumab is a monoclonal antibody; protein binding is not clinically meaningful. Typically, monoclonal antibodies have negligible binding to plasma proteins other than target antigen.
No specific protein binding; Ig G4 monoclonal antibody does not bind significantly to plasma proteins.
Volume of distribution is approximately 5-7 L (or ~0.07 L/kg for a 70 kg patient), indicating distribution primarily in the vascular space.
Vd ~6.0 L (0.08 L/kg for 70 kg adult); primarily confined to vascular space and interstitial fluid.
Empliciti is administered intravenously, thus bioavailability is 100% by IV route. No other routes are approved.
IV administration: 100% bioavailable; no other routes approved.
No dose adjustment required for mild to moderate renal impairment (Cr Cl ≥30 m L/min). Not studied in severe renal impairment (Cr Cl <30 m L/min) or dialysis.
No dose adjustment required for mild to moderate renal impairment (Cr Cl 30-89 m L/min). Not studied in severe renal impairment (Cr Cl <30 m L/min) or ESRD.
No formal studies in hepatic impairment. Use caution in patients with moderate to severe hepatic impairment (Child-Pugh B or C) as exposure may be increased.
No formal studies in hepatic impairment. Use with caution in patients with moderate to severe impairment (Child-Pugh B or C).
Safety and efficacy not established in pediatric patients.
Safety and efficacy not established in pediatric patients.
No specific dose adjustment required; monitor for toxicity due to age-related comorbidities and potential decreased organ function.
No specific dose adjustment recommended; select dose with caution due to higher frequency of decreased hepatic, renal, or cardiac function and concomitant disease or drug therapy.
None
None.
Infusion reactions: Premedicate with acetaminophen, H1 and H2 blockers, and corticosteroids; monitor during infusion; may require interruption or discontinuation,Infections: Increased risk, especially with lymphopenia; monitor for signs and manage promptly,Second primary malignancies: Observed in clinical trials; consider risk,Hepatotoxicity: Elevations in liver enzymes; monitor hepatic function,Interference with serum protein electrophoresis and immunofixation assays: Elotuzumab may produce a band that interferes with detection of M-protein; monitor using alternative methods
Risk of serious infections: Evaluate for active infections prior to initiating therapy; monitor for infections during treatment.,Hypersensitivity reactions: Infusion-related reactions may occur; premedicate and monitor during infusion.,Hematologic effects: Neutropenia, thrombocytopenia, and anemia may occur; monitor blood counts.,Hepatotoxicity: Elevations of liver enzymes have been reported; monitor liver function.,Immunogenicity: Anti-drug antibodies may develop and affect efficacy or safety.,Vaccinations: Live vaccines should not be administered during treatment.
History of severe hypersensitivity reactions to elotuzumab or any of its excipients
Known severe hypersensitivity to siltuximab or any of its excipients.,Active severe infections until infection is controlled.
No specific food interactions with Empliciti have been identified. However, when used in combination with lenalidomide and dexamethasone, patients should avoid grapefruit and grapefruit juice due to potential interaction with lenalidomide metabolism (CYP3A4). Maintain adequate hydration and nutrition as tolerated.
No clinically significant food interactions have been reported. Take with or without food as tolerated.
Pregnancy Category N (not classified). Empliciti (elotuzumab) is a monoclonal antibody. Ig G molecules cross the placenta, with increasing transfer in the second and third trimesters. Based on its mechanism of action (SLAMF7-directed immunostimulatory), there is potential for fetal harm including B-cell depletion and immune alterations. No adequate human data; animal studies have not been conducted. Avoid use during pregnancy unless benefit outweighs risk.
SYLVANT (siltuximab) is a monoclonal antibody (Ig G1) that crosses the placenta in increasing amounts as pregnancy progresses, with the highest transfer in the third trimester. Animal studies have shown no evidence of teratogenicity in cynomolgus monkeys at doses up to 10 times the human clinical exposure. However, there are no adequate and well-controlled studies in pregnant women. Based on its mechanism of action (IL-6 inhibition), there is a potential risk of fetal harm due to interference with normal immune development and hematopoiesis. Therefore, SYLVANT should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
No data on presence in human milk, effects on breastfed infant, or milk production. Human Ig G is excreted in breast milk but not systemically absorbed in significant amounts. M/P ratio unknown. Consider developmental and health benefits of breastfeeding along with maternal need for therapy and potential adverse effects on infant (B-cell depletion).
It is not known whether siltuximab is excreted in human milk. However, maternal Ig G is known to be present in breast milk, and monoclonal antibodies can be excreted in low amounts. The M/P ratio is not available. The effects on the breastfed infant and on milk production are unknown. Because of the potential for adverse reactions in nursing infants from siltuximab, breastfeeding should be discontinued during treatment and for at least 90 days after the last dose.
No pharmacokinetic data in pregnancy. Monoclonal antibodies may have altered clearance due to increased plasma volume. However, no recommended dose adjustment; use with caution. No specific guidelines for dose modification during pregnancy.
No specific dose adjustments are recommended for SYLVANT during pregnancy. However, pharmacokinetic changes in pregnancy (e.g., increased volume of distribution, altered clearance) may occur, but no data are available to guide adjustments. The drug should be used with caution, and the dose should be guided by clinical response and tolerability.
Empliciti (elotuzumab) is an immunostimulatory monoclonal antibody used in combination with lenalidomide and dexamethasone for relapsed/refractory multiple myeloma. Premedicate with diphenhydramine, acetaminophen, and H2 blocker to mitigate infusion reactions (IRs). Monitor for IRs, notably hypotension, bronchospasm, and urticaria, especially during the first dose. Administer corticosteroids prior to empliciti infusion to reduce IR risk. Do not administer as an intravenous push or bolus; use a controlled intravenous infusion. If a dose is missed, administer as soon as possible; do not wait until the next scheduled dose. Empliciti carries a boxed warning for increased mortality when used with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma who are not candidates for transplant. Advise patients of potential teratogenicity with lenalidomide and dexamethasone; ensure pregnancy prevention.
SYLVANT (siltuximab) is an IL-6 antagonist indicated for idiopathic multicentric Castleman disease (MCD). Monitor for infections due to immunosuppression; do not administer live vaccines. Infusion reactions possible; premedicate with antihistamines/acetaminophen if needed. Assess baseline hepatic function, as transaminase elevations may occur. Discontinue if severe infusion reaction or anaphylaxis.
You will receive Empliciti as an intravenous infusion over several hours, and you will be monitored for infusion reactions such as chills, fever, difficulty breathing, or rash.,Before each infusion, you will receive medicines to reduce the risk of infusion reactions, including acetaminophen, an antihistamine, and a corticosteroid.,If you miss an appointment, contact your healthcare provider immediately to reschedule; do not wait until the next scheduled dose.,Empliciti may cause serious infections; report any signs of infection such as fever, cough, or pain.,Avoid pregnancy while on Empliciti combination therapy; use effective contraception and discuss appropriate methods with your doctor.,You may experience fatigue, diarrhea, constipation, or nerve pain; inform your doctor if these become bothersome.
Report signs of infection (fever, chills, sore throat) immediately.,Avoid live vaccines (e.g., MMR, varicella) during treatment and for 3 months after.,Notify your doctor if you experience symptoms of infusion reaction (headache, nausea, dizziness, rash).,Regular blood tests will be required to monitor liver function and blood counts.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about EMPLICITI vs SYLVANT, answered by our medical review team.
EMPLICITI is a Monoclonal Antibody Antineoplastic that works by Elotuzumab is a humanized monoclonal antibody that targets the SLAMF7 (signaling lymphocytic activation molecule F7) receptor expressed on myeloma cells and natural killer (NK) cells. It enhances NK cell-mediated antibody-dependent cellular cytotoxicity (ADCC) via direct activation of NK cells through SLAMF7 and CD16 engagement, and also directly activates NK cells to induce killing of myeloma cells.. SYLVANT is a Monoclonal Antibody Antineoplastic that works by Siltuximab is a chimeric monoclonal antibody that binds to human interleukin-6 (IL-6) and prevents its binding to the IL-6 receptor, thereby inhibiting IL-6-mediated signaling and the downstream inflammatory cascade.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between EMPLICITI and SYLVANT depend on the specific clinical indication. These are both Monoclonal Antibody Antineoplastic agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of EMPLICITI is: 10 mg/kg IV weekly for first 8 weeks, then every 2 weeks thereafter; administer with lenalidomide and dexamethasone.. The standard adult dose of SYLVANT is: 11 mg/kg intravenously every 3 weeks, administered over 1 hour.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between EMPLICITI and SYLVANT in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. EMPLICITI is classified as Category C. Pregnancy Category N (not classified). Empliciti (elotuzumab) is a monoclonal antibody. IgG molecules cross the placenta, with increasing transfer in the second and third trimester. SYLVANT is classified as Category C. SYLVANT (siltuximab) is a monoclonal antibody (IgG1) that crosses the placenta in increasing amounts as pregnancy progresses, with the highest transfer in the third trimester. Anim. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.